PRKCI, in contrast, increased myeloid-derived suppressor cells and decreased cytotoxic T-cell infiltration in ovarian cancer, leading to an immune-suppressive TME (Sarkar et al., 2017). The gene discussed is PRKCI; the disease is ovarian carcinoma.